SRSF6

Across TCGA pan-cancer cohorts, SRSF6 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SRSF6 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SRSF6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRSF6 expression acts as an unfavorable survival marker.

LIHC, HNSC, and LUAD are the cancer types where SRSF6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.128	0.783	.001	36	view →
HNSC	DFS	Median	II,III,IV	0.138	0.697	<.001	27	view →
LUAD	OS	Median	All	0.017	0.812	<.001	24	view →
COAD	OS	Median	II,III,IV	0.117	0.792	<.001	18	view →
BLCA	OS	Median	IV	0.089	0.599	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.208	0.659	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SRSF6–LIHC (OS)

Open the LIHC breakdown →